by Richard Daverman, PhD
February 1, 2014 -- Mindray Medical acquired a controlling stake in Shanghai Long Island Biotec, which makes thrombotic and hemostatic reagent products; Actavis continued its exit from China by selling its interest in a China JV to Zhejiang Chiral Medicine Chemicals; Biogen Idec out-licensed China rights for an eight-drug portfolio, including its flagship MS drugs, to UCB (Euronext: UCB) of Belgium; Wanbang Biopharma in-licensed China rights to a Sirona Biochem pre-clinical diabetes treatment, paying up to $9.5 million; AstraZeneca and the Shanghai Institutes of Biological Sciences agreed to collaborate on a basic research project in cardiovascular disease; Sinovac Biotech filed an application with the CFDA to begin clinical trials of its avian flu A(H7N9) vaccine; and BioTime of California began a concurrent study of its bladder cancer diagnostic test in the US and China. More details….
Stock Symbols: (NYSE: MR) (NYSE: ACT) (NSDQ: BIIB) (TSX: SBM; OTCQS: SRBCF) (NYSE: AZN) (NSDQ: SVA) (NYSE: BTX)
Help employers find you! Check out all the jobs and post your resume.
